In resistant hypercholesterolemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab) are effective and safe choice, hence they do not alter glucose homeostasis and they do not trigger new onset of diabetes (194–196). Here, PCSK9 is linked to diabetes mellitus.